Sidley represented Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, in an exclusive license agreement with Gedeon Richter Plc. to commercialize a relugolix combination tablet for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia and New Zealand. Under the agreement, Myovant will receive an upfront payment of US$40 million and is eligible to receive up to US$40 million in regulatory milestones and US$107.5 million in sales-related milestones and tiered royalties on net sales following regulatory approval. Myovant retains all rights to a relugolix combination tablet in the United States, as well as rights to relugolix in other therapeutic areas outside of women’s health. In addition, Myovant will continue to lead the global development of relugolix combination tablet.
The Sidley team was led by Technology and IP Transactions partner Tom Duley (San Francisco); partner Kristina Nordlander (London) led the EU competition law analysis; partner Dorothee Schramm (Geneva) advised on Swiss law issues; partner Leslie A. Shubert (Washington, D.C.) advised on FCPA compliance issues; senior counsel Stephen Spinks, senior associate Anne Robert and associate Toni Pitesa (Brussels) advised on Antitrust/Competition issues; and associate Rachelle Soderstrom (San Francisco) and associate BinQuan Zhuang, Ph.D. (Palo Alto) advised on Technology and IP Transactions issues.
Complete details are available in the press release.